Overview
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
Description
The aim of the project is to use a combination of patient-derived organoid models:
- To amplify tumour tissue to obtain enough material for genomic and histological analysis
- to characterize the lung cancer sub-type
- To predict treatment (non)response.
The following points will be addressed:
- First, the investigators plan to establish and characterize formation of organoids from biopsies of patients with lung cancer: in spheroids, in the 3D cellular model OncoCilAirTM (OncoTheis), and on the chick chorioallantoic membrane (CAM). Patient-derived organoids from tumoural tissue (PDO) will be characterized and compared to the original tumour.
- Second, the investigators will test the chemoresponse (chemosensitivity and chemoresistance) of organoids to anti-cancer treatment.
Eligibility
Inclusion Criteria:
- Histologically proven lung cancer
- Age ≥ 18
- Written informed and signed consent
- Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour
Exclusion Criteria:
- Less than 18 years of age
- Not able to give informed consent (language, intellectual capacities, etc.)
- Not accessible to biopsy and/or surgery sample
- Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.